Eladocagene Exuparvovec

Summary

Eladocagene Exuparvovec (CHEMBL4298189) is an approved gene (ATC A16AB26); indicated across 1 condition including inborn disorder of amino acid metabolism.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Gene
• ATC class: A16AB26
• Indications: 1 condition
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298189
Name	Eladocagene Exuparvovec
Type	Gene
Max phase	4
ATC	A16AB26

Also known as: AGIL-AADC, Eladocagen exuparvovec, Eladocagene exuparvovec, Kebilidi, Upstaza, ELADOCAGENE EXUPARVOVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
inborn disorder of amino acid metabolism	4	MONDO:0004736	MONDO:0004736

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04903288	PHASE2	ACTIVE_NOT_RECRUITING	A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).